<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455829</url>
  </required_header>
  <id_info>
    <org_study_id>G1T38-03</org_study_id>
    <secondary_id>2017-004315-39</secondary_id>
    <nct_id>NCT03455829</nct_id>
  </id_info>
  <brief_title>G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination With Osimertinib in Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G1 Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>G1 Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to investigate the potential clinical benefit of G1T38 as an oral therapy in
      combination with osimertinib in patients with EGFR mutation-positive metastatic non-small
      cell lung cancer.

      The study is an open-label design, consists of 2 parts: safety, pharmacokinetic, and
      dose-finding portion (Part 1), and randomized portion (Part 2). Both parts include 3 study
      phases: Screening Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase
      begins on the day of first dose with study treatment and completes at the Post-Treatment
      Visit. Approximately, 144 patients will be enrolled in the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2018</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>Cycle 1 Day -14 to Cycle 1 Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 dose</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Treatment Related Adverse Event, including Abnormal Laboratory Events</measure>
    <time_frame>36 months</time_frame>
    <description>All AEs, including clinical laboratory, vitals signs, physical examinations and ECGs will be analyzed in all patients receiving study drug from the signing of the informed consent until 30 days after the last dose of study medication</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival (PFS) using blinded independent central review (BICR)</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response based on RECIST, Version 1.1</measure>
    <time_frame>21 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of G1T38 and metabolite G1T30: Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Part 1, Cycle 1 Day -14 to Day -2. Part 2, Cycle 1 Day 15 to Cycle 2 Day 1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of G1T38 and metabolite G1T30: Area under Curve - plasma concentration (AUC)</measure>
    <time_frame>Part 1, Cycle 1 Day -14 to Day -2. Part 2, Cycle 1 Day 15 to Cycle 2 Day 1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of G1T38 and metabolite G1T30: Plasma: terminal half life (T1/2)</measure>
    <time_frame>Part 1, Cycle 1 Day -14 to Day -2. Part 2, Cycle 1 Day 15 to Cycle 2 Day 1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of G1T38 and metabolite G1T30: Plasma - Volume of distribution</measure>
    <time_frame>Part 1, Cycle 1 Day -14 to Day -2. Part 2, Cycle 1 Day 15 to Cycle 2 Day 1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS using investigator assessment</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year PFS using investigator assessment and BICR</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Lung Cancer</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1: G1T38 + Osimertinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: G1T38 + Osimertinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to receive G1T38 at the dose determined in Part 1 in combination with osimertinib 80 mg, each administered once-daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Osimertinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to receive osimertinib 80 mg once-daily.
At the time of disease progression per RECIST v1.1, patients who were initially randomized to receive osimertinib alone may crossover to receive G1T38 + osimertinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G1T38</intervention_name>
    <description>CDK 4/6 inhibitor</description>
    <arm_group_label>Part 1: G1T38 + Osimertinib</arm_group_label>
    <arm_group_label>Part 2: G1T38 + Osimertinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib</intervention_name>
    <description>EGFR TKI; 80 mg</description>
    <arm_group_label>Part 1: G1T38 + Osimertinib</arm_group_label>
    <arm_group_label>Part 2: G1T38 + Osimertinib</arm_group_label>
    <arm_group_label>Part 2: Osimertinib</arm_group_label>
    <other_name>Tagrisso</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed EGFR mutation for non-small cell lung cancer associated with EGFR TKI
             sensitivity

          -  For Part 2, EGFR T790M mutation-positive tumor status

          -  Left ventricular ejection fraction (LVEF) â‰¥ institution's lower limit of the reference
             range

          -  For Part 1, evaluable or measurable disease as defined by RECIST, Version 1.1

          -  For Part 2, measurable disease as defined by RECIST, Version 1.1

          -  ECOG performance status 0 to 1

          -  Adequate organ function

        Exclusion Criteria:

          -  Prior treatment with EGFR TKI within 9 days of first study dose

          -  For Part 1, prior treatment with more than 2 prior lines of chemotherapy for advanced
             NSCLC

          -  For Part 2, prior treatment with osimertinib or other T790M active EGFR TKI

          -  For Part 2, prior chemotherapy for advanced NSCLC

          -  Active uncontrolled/symptomatic CNS metastases, carcinomatous meningitis, or
             leptomeningeal disease

          -  Investigational drug within 3 months or 5 half-lives, whichever is longer, of first
             study dose

          -  Concurrent radiotherapy, radiotherapy within 28 days of first study dose, previous
             radiotherapy to the target lesion sites, or prior radiotherapy to &gt; 25% of bone marrow

          -  Prior hematopoietic stem cell or bone marrow transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Contact</last_name>
    <role>Study Director</role>
    <affiliation>G1 Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>G1 Therapeutics Clinical Contact</last_name>
    <phone>919-213-9835</phone>
    <email>clinicalinfo@g1therapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beverly Hills Cancer Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Berz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Joseph Heritage Healthcare</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Anderson, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>CDK 4/6 Inhibitor</keyword>
  <keyword>EGFR-Positive</keyword>
  <keyword>EGFR Mutation- Positive</keyword>
  <keyword>T790M</keyword>
  <keyword>EGFR Mutant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

